On May 22, Smoore International rose 3.15% in regular trading, trading at HK$10.15 per share, with trading volume of HK$32.83 million. The stock showed signs of stabilization and rebound after consecutive pullbacks since May 14.

On the news front, the U.S. FDA previously granted its first-ever PMTA approval for a non-tobacco-flavored e-cigarette product, which had driven Smoore International's stock price up over 20% earlier in the month. Following several sessions of profit-taking that brought the stock below HK$10, the current rebound suggests selling pressure may be easing.

Institutions remain bullish on the company's mid-to-long-term outlook, citing its underage-user identification technology as a key factor in FDA approval considerations. Analysts believe the company's core client products and proprietary brands are poised for accelerated regulatory approval, positioning it as a direct beneficiary of compliant market recovery. Additionally, research from CCB International notes that traditional smokers are shifting in large numbers toward new tobacco products, with structural industry improvements expected to drive valuation recovery for related companies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)